Pharmacogenomics of platinum-based chemotherapy in NSCLC

Author： Hildebrandt Michelle AT   Gu Jian   Wu Xifeng  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.5, Iss.7, 2009-07, pp. : 745-755

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy

By García-Campelo Rosario   Alonso-Curbera Guillermo   Antón Aparicio LM   Rosell Rafael  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2015-2026

Informa Healthcare

Access to resources Recommend Favorite

Influence of polymorphisms in MTHFR 677 C→→T, TYMS 3R→→2R and MTR 2756 A→→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC

By Cui Lian-Hua   Yu Zhuang   Zhang Ting-Ting   Shin Min-Ho   Kim Hee-Nam   Choi Jin-Su  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 797-808

Future Medicine

Access to resources Recommend Favorite

ZD 0473: overcoming resistance to platinum-based chemotherapy

By  

Inpharma, Vol. 1, Iss. 1317, 2001-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Gemcitabine + vinorelbine: superior to platinum-based regimens in NSCLC?

By  

Inpharma, Vol. 1, Iss. 1308, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Platinum- and non-platinum-based regimens compared in NSCLC

By  

Inpharma, Vol. 1, Iss. 1288, 2001-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite